Navigation Links
Protalix BioTherapeutics to Dual List on Tel Aviv Stock Exchange
Date:8/30/2010

talix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell based expression system.  Protalix's ProCellEx (TM) presents a proprietary method for the expression of recombinant proteins that Protalix believes will allow for the cost-effective, industrial-scale production of recombinant therapeutic proteins in an environment free of mammalian components and viruses. Protalix is also advancing additional recombinant biopharmaceutical drug development programs.  Taliglucerase alfa is an enzyme replacement therapy in development under a Special Protocol Assessment with the FDA for Gaucher disease.  Protalix's new drug application (NDA) for taliglucerase alfa has been accepted by the U.S. Food and Drug Administration (FDA) and granted a Prescription Drug User Fee Act (PDUFA) action date of February 25, 2011.
For more information on Protalix, visit http://www.protalix.com.

Safe Harbor StatementTo the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995.  These forward-looking statements, including statements relating to the perceived effects of dual listing on the market for our common stock, are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made.  These statements are based on our current beliefs and expectations as to such future outcomes.  Factors that might cause material differences include, among others, risks relating to the trading of our common stock on the Tel Aviv Stock Exchange or the NYSE Amex, risks relating to our continued compliance with the rules of the Tel Aviv Stock Exchange and the NYSE Amex and other
'/>"/>

SOURCE Protalix BioTherapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Protalix Announces Successful GMP Manufacturing Audit by Israels Ministry of Health
2. Integrated BioTherapeutics Awarded NIAID Contract For Up to $65 Million for Development of a Vaccine against Ebola and Marburg Viruses
3. Northwest Biotherapeutics Settles Class Action Complaint, and SEC Investigation Closed Without Action
4. Northwest Biotherapeutics Secures $700,000 Equity Financing
5. Oxygen Biotherapeutics, Inc. Expands Board of Directors
6. Oxygen Biotherapeutics, Inc. Adds Oxycyte TBI Clinical Trial Sites in Israel
7. Webcast Alert: Oxygen Biotherapeutics, Inc. Investor Meeting in Zurich, Switzerland
8. Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry
9. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
10. CSL Limited and Talecris Biotherapeutics Agree to Terminate Merger Agreement
11. Oxygen Biotherapeutics, Inc. Announces Closing of Private Placement Financing Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... , 22. Juli 2014 Qforma, ein ... die Ernennung von Marcus Bergler zum General Manager ... hat die europäischen kommerziellen Aktivitäten von Qforma bereits ... sich Qforma anschloss, war er in Positionen als ... als Vertriebsteam-Leiter Deutschland bei IMS Health und als ...
(Date:7/22/2014)... Greenville, SC (PRWEB) July 22, 2014 ... chorus of those who have recognized that the greatest ... inefficient, and far too often needlessly deadly while trying ... the multitude of quasi-experts seeking to transform an enormous ... detail.” , Dr. Williams, in his continuing series of ...
(Date:7/21/2014)... the right amount of tension to a chain of ... to an insulator, according to Rice University scientists. , ... one-dimensional chain of carbon atoms -- by just 3 ... that engineers might find useful for mechanically activated nanoscale ... physicist Boris Yakobson and his colleagues appears in the ...
(Date:7/21/2014)... 2014  Mike Patterson, CEO of Graphene Frontiers, ... Series Seed B funding to finance production of ... life science, defense, intelligence, and environmental industries.  A ... round and was joined by R2M Investments.  Return ... , "This round of funding will ensure Graphene ...
Breaking Biology Technology:Qforma gibt Schaffung des neuen Postens als General Manager in Europa bekannt 2Dr. Ira Williams Asks What’s Wrong With Jonathan Bush’s Book, Where Does It Hurt? 2Carbyne morphs when stretched 2Carbyne morphs when stretched 3Global Graphene Manufacturing Leader, Graphene Frontiers, Receives Series Seed B Funding To Assure Production Of The Next Generation Of Biological And Chemical Sensor Technology 2
... and TOKYO, Aug. 15, 2011 A new post-hoc ... TRITON-TIMI 38 study – those identified as the "core ... (in combination with aspirin) was associated with a 26 ... of cardiovascular death, myocardial infarction or stroke, compared to ...
... team of researchers from the National Institute of ... the University of Maryland has made nano-sized sensors ... paints, cleaners, pesticides and other productsthat offer several ... room-temperature operation and the ability to detect one ...
... and portable detector that takes just fifteen minutes to ... being developed by US researchers. The technology amplifies any ... the presence of just 40 microscopic cells of the ... as anthrax, is a potentially lethal microbe that might ...
Cached Biology Technology:Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 2Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 3Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 4Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 5Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 6Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 7Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 8Nanowire-based sensors offer improved detection of volatile organic compounds 2Nano detector for deadly anthrax 2
(Date:7/22/2014)... as a world-famous vacation spot with natural tourism resources, a ... The Korea Institute of Geoscience and Mineral Resources (KIGAM) indicated ... volcanic eruption was evident 5,000 years ago. That is the ... spewed out of a volcano 5,000 years ago in the ... the whole peninsula. , The research team led by Dr. ...
(Date:7/22/2014)... prevent their daughters from breeding, and kill their grandchildren ... desert creatures which live in groups with a dominant ... alpha female can flourish when it maintains the sole right ... life, also found in many animals such as ants and ... Dominant meerkats control breeding within their group through violence, by ...
(Date:7/22/2014)... July 22, 2014, Cleveland: A type of immune ... diseases, such as Alzheimer,s disease and multiple sclerosis ... brain injury (TBI) and may slow the progression ... published today in the online journal Nature ... Bruce Trapp, PhD, Chair of the Department of ...
Breaking Biology News(10 mins):Jeju Island is a live volcano 2Cleveland Clinic researchers discover neuroprotective role of immune cell 2
... (HLB), meaning "yellow shoot disease" in Chinese and ... the most destructive disease threatening the citrus industry ... are desired to control it. A new study, ... contributing factor in symptom expression for citrus Huanglongbing ...
... The Alfred P. Sloan Foundation is pleased to announce ... as recipients of Sloan Research Fellowships for 2013. ... to early-career scientists and scholars whose achievements and potential ... scientific leaders. "The Sloan Research Fellows are the ...
... Research Centre at Saint Mary,s Hospital and The University ... causing an inherited form of tumour, known as spinal ... Meningiomas are the commonest form of tumour affecting the ... surgery and do not recur. Occasionally people can develop ...
Cached Biology News:Phosphorus starvation linked to symptoms of citrus disease Huanglongbing in new study 2Phosphorus starvation linked to symptoms of citrus disease Huanglongbing in new study 3Sloan Foundation announces 2013 Sloan Research Fellows 2Researchers in Manchester find genetic key to preventing spine tumors 2
... stain has bright fluorescence when bound to dsDNA ... for detecting dsDNA in gels using laser scanners ... nucleic acid stain has also found uses ... bandshift assays. A 500 µL unit size (S-7563) ...
... cross-linking techniques are defined by the author ... Wong. This valuable hardcover guide includes hundreds ... application references. More than 300 pages detail ... conjugate preparation from selection and design ...
... protein separation by two-dimensional electrophoresis (2D-PAGE), ... package from Bio-Rad and protein identification ... to meet customers requirements regarding experimental ... format of the results permanent contact ...
... reagents for immune complex disruption (ICD) of ... using a combination of low pH and ... transferred to microplate wells which are coated ... to HIV-1 p24. The immobilized monoclonal antibody ...
Biology Products: